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Diabetes mellitus (DM) affects an estimated 15
million Americans1 and is well established as an
independent risk factor for the development of ath-
erosclerosis.2 More than 90% of patients with DM
suffer from type 2 DM, which is characterized by
insulin receptor resistance resulting in hyperglycemia
and increased serum insulin levels. Although athero-
sclerosis is a systemic disease, the lower-extremity
infragenicular vessels seem to be at increased risk for
the development of severe arterial occlusive disease
in patients with DM. Significant peripheral vascular
disease (PVD), usually involving the tibial vessels, is
present in 12% of patients with type 2 DM, and it
frequently results in limb-threatening ischemia.3
Forty-five percent of all lower-extremity amputa-
tions are performed in patients with DM. The 5-year
survival rate after a major amputation is 30%.
Another 30% of patients require a contralateral
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Purpose: Peripheral vascular disease involving the infragenicular arterial tree is common
in patients with diabetes mellitus (DM). Accelerated proliferation of vascular smooth
muscle cells (VSMCs) plays an important role in the development of atherosclerosis.
Insulin and glucose stimulate VSMC proliferation and are elevated in patients with
non–insulin-dependent DM. We have previously described the mitogenic effect of insulin
on VSMCs in vitro; the effects of insulin and glucose separately and in combination on
the proliferation of VSMCs grown in serum-free media were studied.
Methods: Human infragenicular VSMCs isolated from diabetic patients with end-stage
peripheral vascular disease undergoing below-knee amputation were used. Cells from
passages 3 to 5 were grown in serum-free media with varying glucose (0.05%, 0.1%,
0.2%, 0.4%, 0.6%, and 0.8%) and insulin (no added insulin, 100 ng/mL, and 1000
ng/mL) concentrations for 6 days.
Results: Insulin stimulated VSMC growth at glucose concentrations more than 0.2%
(0.4% glucose with no added insulin resulted in 13,073 ± 336 cells/mL, 0.4% glucose
with 100 ng/mL insulin resulted in 16,536 ± 1175 cells/mL, 0.4% glucose with 1000
ng/mL insulin resulted in 17,500 ± 808 cells/mL, 0.6% glucose with no added insulin
resulted in 14,167 ± 1062 cells/mL, 0.6% glucose with 100 ng/mL insulin resulted in
18,984 ± 1265 cells/mL, 0.6% glucose with 1000 ng/mL insulin resulted in 20,450 ±
1523 cells/mL, 0.8% glucose with no added insulin resulted in 15,853 ± 1650 cells/mL,
0.8% glucose with 1000 ng/mL insulin resulted in 26,302 ± 1919 cells/mL; P < .05
compared with glucose with no added insulin). Glucose stimulated VSMC proliferation
up to a concentration of 0.2% (42% and 117% higher growth at 0.1% and 0.2% glucose,
respectively, compared with the baseline, P < .05), regardless of the insulin concentra-
tion in the media. The greatest growth (26,302 ± 1919 cells/mL) occurred in the group
with the highest concentration of both insulin (1000 ng/mL) and glucose (0.8% glu-
cose; P < .05).
Conclusion: Both insulin and glucose stimulate the growth of diabetic infragenicular
VSMCs. The mitogenic effects of insulin and glucose are additive and may contribute to
the development of atherosclerosis in patients with DM. (J Vasc Surg 1998;28:1033-9.)
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amputation within 3 years.4 Below-knee revascular-
ization procedures are characteristically challenging,
but necessary for limb salvage.3
The pathogenesis of atherosclerosis has been
studied extensively. The migration and proliferation
of vascular smooth muscle cells (VSMCs) within the
intimal layer of the arterial wall occurs early in the
disease process, along with a phenotypic change
from the contractile to synthetic state.5-7 The role of
insulin in the development of atherosclerosis was
first postulated by Stout in 1975,8 and later it was
confirmed by others. More recently, insulin has been
shown to stimulate the growth of VSMCs in culture.
The resistance of insulin cell membrane receptors to
insulin in patients with type 2 DM causes glucose
intolerance and an increased production of insulin
by the pancreas in response to the resultant hyper-
glycemia.9 This increased production of insulin may
stimulate the proliferation of VSMCs, promoting
the initiation and progression of atherosclerosis in
patients with DM. Hyperglycemia has also been
identified as an independent risk factor for the devel-
opment of atherosclerosis.10
We attempted to quantify the effects of insulin
and glucose, alone and in combination, on the
growth of cultured human infragenicular VSMCs
that were taken from patients with DM and grown
in serum-free media.
MATERIALS AND METHODS
Cell harvesting, isolation, and characteriza-
tion. Segments of human infragenicular arteries
were harvested from 7 patients undergoing below-
knee amputations for end-stage PVD at the
Washington, DC, Veterans Affairs Medical Center.
All donors were men between the ages of 55 and 70
years who had type 2 DM. Prior consent was
obtained in accordance with the medical center’s
institutional review board. After rinsing with
Dulbecco’s phosphate-buffered saline solution
(PBS, Gibco, Grand Island, NY), the adventitia, inti-
ma, and calcific atherosclerotic plaque were careful-
ly dissected away from the arterial wall, leaving a seg-
ment comprised primarily of media. The samples
were minced and subjected to enzymatic dispersion
with 0.8% collagenase and 0.05% elastase
(Worthington Biochemical, Freehold, NJ), with the
technique of Parkes.11 The sample was agitated in a
37°C water bath for approximately 3 hours, at which
time the solution became cloudy. The suspension
was centrifuged at 2000 rpm for 2 minutes, and the
supernatant was removed. The resultant cellular pel-
let was rinsed with PBS and resuspended in enriched
media. The enriched media consisted of Media-199
(Gibco) supplemented with 10% fetal bovine serum
(FBS, Gibco) and 1% antibiotic antimycotic (10,000
U/mL penicillin G sodium, 10,000 m g/mL strepto-
mycin sulfate, and 25 m g/mL amphotericin B;
Gibco). The suspension was seeded in 25 cm2 cell
culture flasks and incubated at 37°C in 5% CO2 until
the cells grew to confluence. The resultant cultures
were identified as VSMCs by immunohistochemical
staining techniques for a -smooth muscle actin,
myosin, vimentin, vitronectin, desmin, chondroitin
sulfate, and fibronectin, as previously described.12
Passages 3 to 5 were used for all subsequent experi-
ments.
Proliferation assays. Subconfluent VSMCs
were rinsed with PBS and detached using 0.25%
trypsin ethylenediamine tetra-acetic acid (Gibco) to
produce a single cell suspension. The cellular sus-
pension was centrifuged at 2000 rpm for 2 minutes
and rinsed with warm PBS 3 times. The final pellet
was resuspended in enriched media to a density of
5000 cells/mL, and 2 mL was plated into each well.
Forty-eight hours were allowed for cell attachment,
then the enriched media was replaced with serum-
free media, and the cells were subjected to 24 hours
of serum starvation. Serum-free media consisted of
Media-199 with 1% antibiotic antimycotic, but not
FBS. Cells were counted after the 24-hour period of
serum starvation, and this value was used as the
baseline value against which statistical comparisons
were made. After 24 hours of serum starvation, glu-
cose was added to the wells to obtain a final glucose
concentration of 0.05%, 0.1%, 0.2%, 0.4%, 0.6%, or
0.8%. Insulin (Bovine pancreas, SIGMA Chemical,
St Louis, Mo) was added at a concentration of 100
ng/mL or 1000 ng/mL to two thirds of the wells in
each group of glucose concentrations, with the
remaining third of the wells receiving no additional
insulin. Serum-free media with no added insulin has
an insulin concentration of 7 ng/mL. This is the
minimum concentration of insulin required to main-
tain viable VSMCs in culture. There were a total of
8 experiments for each combination of glucose and
insulin concentration. Each experiment was run in
triplicate. After 6 days of growth in 5% CO2 at 37°C,
the cells were washed with cold PBS and resuspend-
ed with 0.25% trypsin ethylenediamine tetra-acetic
acid (Gibco). Cell counts were performed on each
well with standard hemocytometry. The counts were
repeated 3 times, and the mean value was used for
statistical analysis.
Statistical analysis. All values are reported as
means ± standard error of the mean. A one-way
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analysis of variance test was used. All pair wise multi-
ple comparison procedures (Tukey test or Student-
Newman-Keuls method) were used for post hoc
analysis. A value of P < .05 was considered significant.
RESULTS
All groups, except the group grown in 0.05%
glucose with no added insulin (7104 ± 914
cells/mL), showed a significant increase in cell den-
sity (P < .05) compared with the baseline of 6328 ±
228 cells/mL, as shown in Fig 1. The rate of cell
growth consistently increased as the concentrations
of glucose and insulin were increased in the media,
with the greatest growth (26,302 ± 1919 cells/mL)
occurring in the group with the highest concentra-
tion of both insulin (1000 ng/mL) and glucose
(0.8% glucose).
Increasing the concentration of either glucose or
insulin alone in the media resulted in a significantly
increased rate of VSMC growth. When the concen-
tration of glucose remained constant and the con-
centration of insulin in the media was increased, the
VSMCs showed increased growth (Fig 1). At glu-
cose concentrations of 0.2% or less, this trend was
not significant. With glucose concentrations of 0.4%
or more, a statistically significant increase in cell
growth occurred when insulin was added to the
media. When grown in media with a glucose con-
centration of 0.4%, the cells grew to a density of
13,073 ± 336 cells/mL with no added insulin,
16,536 ± 1175 cells/mL with 100 ng/mL of addi-
tional insulin (P < .05, compared with no added
insulin), and 17,500 ± 808 cells/mL with 1000
ng/mL of additional insulin (P < .05, compared
with no added insulin). At a glucose concentration
of 0.6%, the cells reached a density of 14,167 ± 1062
cells/mL with no added insulin, 18,984 ± 1265
cells/mL with 100 ng/mL of additional insulin (P <
.05, compared with no added insulin), and 20,450 ±
1523 cells/mL with 1000 ng/mL of additional
insulin (P < .05, compared with no added insulin).
When the glucose concentration was increased to
0.8%, the cells grew to a density of 15,853 ± 1650
cells/mL with no added insulin, compared with
26,302 ± 1919 cells/mL with 1000 ng/mL of addi-
tional insulin (P < .05, compared with no added
insulin).
Similarly, when the concentration of insulin in
the media was kept constant and the concentration
of glucose increased, there was an increase in the
rate of cell growth (Fig 2). This effect was most
noticeable between glucose concentrations of 0.1%
and 0.2% (no added insulin and 0.1% glucose result-
ed in 10,074 ± 970 cells/mL vs 0.2% glucose, which
resulted in 15,414 ± 1828 cells/mL; 100 ng/mL of
additional insulin with 0.1% glucose resulted in
11,354 ± 1175 cells/mL vs 0.2% glucose, which
resulted in 17,083 ± 2141 cells/mL; 1000 ng/mL
of additional insulin and 0.1% glucose resulted in
12,854 ± 1831 cells/mL vs 0.2% glucose, which
resulted in 18,125 ± 2206 cells/mL; P < .05). Cells
grown in glucose concentrations of 0.2% or greater
had significantly higher growth than those grown in
glucose concentrations of 0.1% or less (P < .05),
regardless of the insulin concentration. When the
concentration of glucose was increased above 0.2%,
there was no additional increase in cell growth in the
groups with no added insulin or 100 ng/mL of
additional insulin. Cells grown in media with 1000
ng/mL of additional insulin did show an increase in
growth when the glucose concentration was
increased from 0.6% to 0.8% (20,450 ± 13,125
cells/mL vs 26,302 ± 1919 cells/mL, P < .05).
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Fig 1. The effect of insulin concentration on cell growth
at each concentration of glucose studied. Each value rep-
resents the mean number of cells obtained. All values are
statistically different from the baseline value, except 0.05%
glucose with no added insulin. 
*P < .05, compared with the same concentration of glu-
cose with no added insulin
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DISCUSSION
DM is a significant clinical problem in the
United States, affecting 6.6% of the adult popula-
tion.1 Limb-threatening ischemia, caused by athero-
sclerotic lower-extremity PVD, is one of the most
common and most costly morbidities associated
with DM.2 VSMCs are major participants in the
development of atherosclerosis. The migration of
VSMCs from their normal location in the media of
the arterial wall to the intima is one of the earliest
events in the formation of atherosclerotic plaque.5,6
The cells then undergo a phenotypic change from
the contractile to the synthetic state. The prolifera-
tion of the VSMCs within the intima forms the core
of the atherosclerotic plaque. Lipids and connective
tissue form the remainder of the mature atheroscle-
rotic plaque. An understanding of the factors that
control the migration and proliferation of the
VSMCs is essential to understanding the pathogen-
esis of atherosclerosis. Many factors, including
insulin and glucose, are believed to influence the
proliferation of VSMCs.5,6,13,14 Type 2 DM is char-
acterized by insulin receptor resistance, hyper-
glycemia, and hyperinsulinemia. Both insulin13-17
and glucose18,19 have been postulated to have roles
in the formation of atherosclerotic plaques and may
be responsible for the accelerated atherosclerosis
seen in patients with type 2 DM.9,20
Previous studies have shown that VSMCs in cul-
ture remain in the contractile state during early pas-
sages, but after 8 to 10 passages undergo phenotyp-
ic transformation into a predominantly synthetic
population.21,22 These phenotypic changes have
been seen to take place earlier if cells are kept in
enriched media.12, 23 All experiments were done in a
serum-deprived environment to eliminate the effects
of other potential growth factors on VSMCs and to
isolate the effects of insulin and glucose on cell pro-
liferation. We have previously shown that 10% serum
maintained a stable population, causing a nonsignif-
icant increase in cell number. Higher serum concen-
tration (20%) caused significant increase in the pro-
liferation of VSMCs.13
Our results show a significant mitogenic effect of
both glucose and insulin alone and in combination
on diabetic VSMCs grown in serum-free media. The
glucose effect was most prominent between glucose
concentrations of 0.1% and 0.2%, with little increase
in growth occurring if the concentration of glucose
was more than 0.2%. Cells exposed to a glucose con-
centration of 0.2% or greater, had significantly
increased growth rates compared with those grown
at the physiologic glucose concentration of 0.1%.
This stimulation of cell proliferation was indepen-
dent of the concentration of insulin in the media.
The concentrations of glucose used in this study
were chosen to simulate the levels seen in patients
with DM. Patients with DM frequently maintain
serum glucose concentrations between 0.2% and
0.4%. It was at this level that the effects of glucose
on VSMCs proliferation seemed to peak. These find-
ings support the clinical data suggesting that hyper-
glycemia is an independent risk factor for the devel-
opment of atherosclerosis.10
The results with insulin were equally striking. As
the concentration of insulin in the media was
increased, cell growth was stimulated at all glucose
concentrations. This trend was not significant at glu-
cose concentrations of 0.2% or less, but reached sta-
Fig 2. The effect of glucose concentration on cell growth
at each concentration of insulin studied. Each value repre-
sents the mean number of cells obtained. 
*P < .05, compared with the previous glucose concentration. 
#P < .05, compared with the baseline and glucose concen-
trations of 0.05% and 0.1%.
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tistical significance when the concentration of glu-
cose was more than 0.2%. The normal fasting insulin
level is 100 ng/mL.24 This increases several times
with oral glucose intake. Patients with type 2 DM
characteristically demonstrate insulin resistance and
consequently have increased insulin production. It is
not uncommon for insulin levels to rise above 1000
ng/mL in these patients.24 At the physiologic
insulin concentration of 100 ng/mL, there was
stimulation of cell growth, but less than that seen at
the elevated insulin concentration of 1000 ng/mL.
Once again, this is consistent with the clinical data
suggesting that insulin stimulates the progression of
atherosclerosis.18
The greatest stimulation to cell growth occurred
when both the glucose and insulin concentrations
were elevated above normal physiologic levels. The
mitogenic effects of glucose and insulin appeared to
be additive as their serum concentrations were
increased. Patients with type 2 DM frequently main-
tain serum glucose concentrations higher than 0.2%
and demonstrate insulin resistance, with serum
insulin levels elevated to more than 1000 ng/mL.
These are the concentrations that resulted in the
highest rate of VSMC proliferation in our study.
This observation may have significant clinical impli-
cations. Insulin therapy for type 2 DM will increase
the already elevated serum insulin levels present in
these patients. The combination of both elevated
glucose and insulin levels may increase the prolifera-
tion of VSMCs, resulting in accelerated progression
of atherosclerosis. Newer therapeutic agents such as
troglitazone enhance insulin function, reducing
insulin resistance and pancreatic insulin production.
This may offer a significant advantage over tradi-
tional insulin therapy. By decreasing both glucose
and insulin concentrations, the proliferation of
VSMCs may be slowed, resulting in slower progres-
sion of atherosclerosis. It is not clear whether the
mitogenic effects of insulin are mediated via the
insulin receptor; ongoing studies are designed to
elucidate this mechanism. In addition, VSMCs cul-
tured from arterial sources other than the infra-
genicular area may react the same as infragenicular
VSMCs in response to insulin and glucose, because
atherosclerosis is a generalized disease in patients
with DM.
This investigation offers direct evidence that glu-
cose and insulin have an additive effect on the pro-
liferation of diabetic VSMCs in vitro. This correlates
with the clinical finding that patients with elevated
insulin and glucose levels are at increased risk for the
development of atherosclerosis.18 Insulin therapy
currently used in the treatment of type 2 DM may
result in increased VSMC proliferation, acceleration
of atherosclerosis, and earlier development of the
complications of DM related to atherosclerosis. This
may have significant clinical implications in the
future treatment of patients with DM.
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DISCUSSION
Dr Frank W. LoGerfo (Boston, Mass). I first want to
compliment Dr Avena on his clear presentation and also
on his well-written manuscript, which he kindly provided
well in advance of this meeting. There is extensive litera-
ture on the effects of insulin on cell growth, much of
which focuses on endothelial cells. There is no study of
which I am aware involving smooth muscle cells from ath-
erosclerotic arteries in patients with diabetes mellitus. I
think this illustrates the value of having surgeons involved
in research, because surgeons understand where the lesion
is and what the practicalities are in getting tissue for study.
This work shows how insulin resistance alone, with
increased insulin levels, can enhance atherogenesis by
increasing the proliferation of smooth muscle cells. Once
overt glycemia occurs with type 2 diabetes mellitus, the
insulin levels often begin to decline. But as shown today, the
glycemia itself can enhance smooth cell growth and, there-
fore, atherogenesis. This work from Dr Sidawy’s laboratory
illustrates nicely how these stimuli may function indepen-
dently or synergistically. The debate has gone on for years as
to whether it is insulin or glucose that results in enhanced
atherogenesis. The answer from these data seems to be it
can be either or both synergistically, probably explaining
why it’s been so difficult to point to one or the other.
The mitogenic effects of insulin on endothelial cells
seem to be mediated by a glucose-independent pathway,
ultimately leading to activation of mitogen-activated pro-
tein kinase. The glucose pathway is through activation of
protein kinose C first and then mitogen-activated protein
kinase. Smooth muscle cells differ from endothelial cells in
that insulin is not involved in glucose transport. Hence,
the synergistic effect in these studies must be independent
of that linkage. Again, this underlines the particular value
of this work, because it is based very specifically on early
passage smooth muscle cells from atherosclerotic arteries
in patients with diabetes mellitus.
This work raises several questions.
First, as far as technique is concerned, were these
pooled smooth muscle cells from several donors? If so,
how many? Or were they run in parallel? And if so, then
how many are in each group?
There seems to be a relative flattening of the curve for
glucose concentrations above 0.2%, as was pointed out by
Dr Avena. However, the insulin enhancement continues
beyond that high level of glucose. Can we deduce any-
thing from this? Is there a limit on glucose transport high-
er than 0.2%? And if that is the case, then how do we
explain the synergistic enhancement? Is there something
that’s actually occurring at the cell membrane level that
leads to the enhancement?
Are there any differences between these effects on
smooth muscle cells and those on endothelial cells, to
which it has been alluded?
Do you have any thoughts about points of interven-
tion that are available today, such as inhibition of protein
kinase C or the use of troglitazone, which diminishes
insulin resistance? I suppose these are areas for further
investigation.
Do you think there is any difference in the comparison
with smooth muscle cells from other arteries, unaffected
arteries, or from veins?
This continued work on the biology of smooth mus-
cle cells from atherosclerotic arteries in this laboratory rep-
resents an important step toward understanding the
mechanism of enhanced atherogenesis of diabetes melli-
tus. I look forward to this continued work, which I think
has earned its place in the literature, especially because it
focuses directly on the lesion itself.
My thanks to the Society for their kind invitation to
comment on this excellent work.
Dr Ricardo Avena. Thank you, Dr LoGerfo, for your
comments. I’ll try to answer your questions in order.
First, regarding the number of donors: we had 7
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donors in our smooth muscle cell proliferation studies.
The experiments were run in parallel. We repeated the
experiments 8 times. Each time, the experiment was done
in triplicate.
Regarding the effects of glucose on proliferation,
indeed, we consistently noted a plateau in growth at con-
centrations higher than 0.2% when no insulin was added
to the media. However, the presence of insulin at either
physiologic or pathologic levels showed “enhanced” cell
proliferation beyond that plateau. So far, we do not have a
clear explanation about the mechanisms of this effect at
the molecular level. We can only hypothesize that glucose
has a limited proliferation potential. Proliferation can be
enhanced by increasing insulin, a mitogen that functions
via a tyrosine kinase receptor.
We haven’t done any proliferation studies on endothe-
lial cells in subjects with diabetes mellitus; however, it is
conceivable that they could also have an additive prolifer-
ation effect when exposed to higher than normal levels of
glucose and insulin.
The question concerning troglitazone is one that we
have actively been working on clinically for some time
now. The data from our clinical study were presented yes-
terday. The study focuses on the effects of troglitazone on
the growth of human diabetic smooth cells in the presence
of glucose and insulin.
Your question about the effects of glucose and insulin
on cells cultured from other arteries is an interesting one.
At the moment, we have focused our work on the infra-
genicular arteries that are most commonly affected in
patients with diabetes mellitus. However, considering that
atherosclerosis is a generalized process, it is conceivable
that the same effects are applicable to other arteries.
Dr Prasad V. Gade (Brooklyn, NY). I congratulate you
on your excellent work. I have 2 questions.
First, did you look at patients without diabetes melli-
tus? Are they congenitally different from patients with dia-
betes mellitus, or is it only the glucose and insulin that’s
variable?
Second, did you take the samples from the same artery,
or are the samples from different arteries? I ask because
there could be site-specific changes in their behavior.
Dr Avena. Your first question is an excellent one, and
one that has been raised before. We have been trying to
culture infragenicular cells from patients without diabetes
mellitus who are undergoing amputation. This has been
somewhat rare in our practice. We have done it on 3 occa-
sions. All 3 cultures showed a much smaller number of
cells after enzymatic dispersion. In addition, we have
noted that those cells grow at a slower rate than cells from
patients with diabetes mellitus, at least in the beginning of
the process. We have not had the opportunity to do pro-
liferative studies on these cells. However, we will continue
our efforts to culture nondiabetic cells and repeat the pro-
liferation experiments in patients without diabetes mellitus
in the future.
To answer your second question, we always obtain our
specimens from the posterior tibial artery, and when pos-
sible, the peroneal artery as well. However, all cells were
pooled. We did not conduct artery-specific experiments. 
